查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1840888

抗精神病药物市场（依药物类别、给药途径、通路、剂型和适应症划分）－2025-2032 年全球预测

Antipsychotic Drugs Market by Drug Class, Route Of Administration, Distribution Channel, Formulation, Indication - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年抗精神病药物市场规模将成长至 196.5 亿美元，复合年增长率为 8.25%。

主要市场统计数据
基准年2024年 104.2亿美元
预计2025年 112.8亿美元
预测年份：2032年 196.5亿美元
复合年增长率（%） 8.25%

全面、情境化的介绍，阐述了改变抗精神病治疗途径的临床要求、交付模式和相关人员的优先事项

抗精神病治疗领域正处于临床需求、政策压力和商业性转型的交会点。近年来，分子药理学的进步、製剂技术的改进以及治疗模式的转变，深刻地改变了临床医生和医疗保健系统对思觉失调症和双相情感障碍的治疗方式。患者对药物耐受性和疗效的要求日益提高，支付方要求药物具有可证明的价值，製造商必须在生命週期管理和新产品开发之间取得平衡。

在此背景下，策略性相关人员需要简洁的方向，重点在于突显影响处方行为、处方投放和病患依从性的驱动因素。为此，既要考虑第一代抗精神病药物的传统作用，也要考虑第二代抗精神病药物不断拓展的治疗空间，同时也要认识到不断变化的给药途径和分销管道如何影响现实世界的药物可及性。本介绍为这些动态提供了一个框架，并为更详细的分析奠定了基础，其核心主题是临床结果、供应链连续性和付款人参与。

分析重新定义抗精神病治疗模式和相关人员期望的临床、技术和证据生成力量的融合。

在以患者为中心的医疗模式、药理学创新和医疗体系现代化的推动下，抗精神病药物领域正在发生重大变革。精准药物选择的意义不仅在于控制症状，还在于降低代谢风险、改善认知功能和长期功能恢復。同时，製剂科学正在催生新的给药方案，从而提高患者依从性并降低復发风险，从而改变住院和门诊病人治疗方案的计算方式。

同时，数位医疗工具和远距精神病学正在扩大诊断范围，并使得对治疗反应和副作用的监测更加密切。这些技术正开始影响处方模式，促进临床医生和患者之间的共用决策，并使持续评估更加可行。此外，对真实世界证据的日益重视正在改变支付方用于制定承保决策的证据标准，医疗保健系统越来越重视长期疗效和利用率指标，而非单一的临床试验终点。这些综合变化迫使製造商比以往任何时候都更加紧密地协调临床开发、商业策略和上市后证据的产生。

重点评估近期美国关税变化如何改变抗精神病药物商业化的供应链策略、采购选择和竞争定位

关税等政策措施可能会对整个医药价值链产生重大的下游影响，尤其是涉及原料药、特殊辅助材料和成品进口时。对于依赖跨境采购原料药和最终产品的製造商和经销商而言，2025年将是一个不确定性加剧的时期。因此，筹资策略策略正转向注重供应商多元化和库存弹性，而商业团队也正在重新评估各个分销管道的服务成本假设。

这些与贸易相关的动态也会影响竞争格局。当关税压力导致进口产品的到岸成本上升时，拥有国内或週边生产能力的製造商享有相对的商业性弹性。相反，依赖复杂国际供应链的公司可能会优先考虑合约对冲、供应商重新谈判和营运投资，以降低风险。因此，贸易政策的不确定性可能会加速战略倡议，例如本地化生产、加强原料药供应的垂直整合以及与区域製造外包更紧密地合作。重要的是，虽然现有的安全性和有效性标准适用于临床专案和监管提交，但产品发布和生命週期计画的时间表可能会受到物流限制和成本控制决策的影响。

可操作的细分洞察，涵盖药物类别、给药途径、分销管道、剂型和适应症，以优化临床应用和商业性重点

稳健的细分能够清楚展现临床需求、应用模式和机会的交会点。依药物类别划分，市场分为第一代抗精神病药物（包括氯丙嗪、氟奋乃静、Haloperidol、奋乃静和硫利达嗪）和第二代抗精神病药物（包括Aripiprazole、氯氮平、Olanzapine、QuetiapineRisperidone）。每类药物的治疗特性、耐受性和处方者偏好各不相同，进而影响其定位策略。

根据给药途径，产品分为注射剂和口服剂型，其中註射剂又分为肌肉注射和长效注射。分销管道包括医院、线上药局和零售药局，这些管道决定着病患的用药模式、配药实践和付款人互动。剂型分类，例如口溶锭、液体製剂和片剂，会影响患者的接受度和诊疗机构的决策。最后，双极性情感障碍和思觉失调症的适应症细分凸显了临床路径、预期治疗持续时间和疗效指标的差异。这种细分有助于制定有针对性的上市方案、制定循证计划，并根据临床和商业性实际情况确定产品组合的优先顺序。

区域战略讯息，检验不同的医疗保健系统、报销框架和获取动态如何影响全球市场上抗精神病药物的采用

区域驱动因素持续以不同的方式影响临床实践、监管解读和分销物流。在美洲，医疗保健服务提供趋势强调整合的行为健康服务、扩大社区护理，以及以结果和成本效益为优先的、由付款人主导的价值评估。这些因素影响处方集的配置决策，推动了对长效注射剂的投资，而这些注射剂的依从性挑战会导致可避免的使用。

在欧洲、中东和非洲，监管协调工作与区域特定的报销方法并存。根据各国国家卫生技术评估流程和资金筹措重点，该地区新药和新配方的采用率各不相同。製造商必须客製化其证据包和定价策略，以满足不同国家的需求。在亚太地区，快速的都市化、不断扩大的保险覆盖范围以及日益增强的精神健康意识，正在推动对各种获取途径的需求，包括口服疗法和数位化依从性工具。在所有地区，供应链的弹性、法规遵循以及符合文化背景的病人参与对于产品的成功发布和持续采用至关重要。此外，地缘政治和政策变化可能导致采购和分销的地区差异，商业策略必须做出相应调整。

公司层面的竞争考察，重点在于产品组合深度、配方创新和策略伙伴关係，从而推动抗精神病药物领域的竞争优势

抗精神病药物的竞争定位反映了传统产品组合、创新剂型和差异化临床证据的整合。现有企业透过平台药物和广泛的分销网络保持显着的市场地位，而专业的创新企业则专注于提高耐受性、依从性和长期功能疗效。原厂药与製造外包之间的伙伴关係在规模化生产方面仍然很常见，而与技术提供者的合作在依从性和监测解决方案方面也日益重要。

开发平臺既注重渐进式创新，例如改进给药系统和配方，也注重针对具有更佳代谢特征的症状区域的新机制。商业性成功的团队将生命週期管理与现实世界证据累积相结合，优先考虑早期付款人的参与，并保持灵活的供应策略以降低交易和采购波动。此外，在监管和卫生经济学专业知识方面的人才投资正成为核心竞争力，使公司能够应对复杂的报销环境并展现相对价值。

为製造商和相关人员提供策略建议，以增强抗精神病药物的弹性、证据生成和付款人友好的商业化

产业领导者应采取协调一致的策略，在短期营运韧性与长期临床差异化之间取得平衡。首先，透过多元化原料药和辅料的采购、尽可能扩大近岸生产以及建立透明的库存和紧急时应对计画来加强供应链。这将降低您受贸易相关中断影响的风险，并支援所有管道的可预测产品供应。

其次，我们将投资于直接应对依从性和耐受性挑战的配方和给药创新，例如长效注射剂和口溶锭，同时将这些产品与数位化依从性监测解决方案相结合，以产生令人信服的真实世界证据。第三，我们将积极吸引付款人，开发基于结果的证据包，以反映长期效益并减少医疗保健利用率。第四，我们将采用灵活的商业模式，根据当地管道动态（包括医院药房、线上药房和零售药房）调整我们的销售策略，并优先考虑促进药物启动和依从性的患者援助计画。最后，我们将培养跨职能能力，例如卫生经济学、监管策略和数据分析，以确保我们的临床价值提案能够转化为报销和持续采用。

一种透明的调查方法，结合临床文献综合、专家访谈和供应链分析，以支持可辩护的策略结论

本研究综合整合了多个来源的证据，为策略决策提供了透明且可重复的依据。调查方法结合了同行评审临床研究的系统性文献综述、监管指南和药品说明书变更分析，以及对临床专家、付款方和商业领袖的结构化访谈，以捕捉真实世界的观点。此外，供应链评估利用物流和采购数据来评估采购依赖和区域製造足迹。

将定性输入与处方模式和医疗服务提供趋势的二手资料进行交叉比对，以得出稳健的主题结论。在可能的情况下，研究结果透过专家咨询小组检验，以确保其现实相关性并揭示预测风险。这种方法强调资料来源的可追溯性和分析假设的清晰度，使相关人员能够在适当的临床和商业性背景下解读结论。随着贸易和监管格局的演变，动态的政策和关税环境需要定期重新评估。

明确的总结性总结强调了临床差异化、证据生成和稳健的商业化策略的一致性，以实现长期影响

总而言之，抗精神病治疗领域正处于曲折点，临床预期、付款人督导和商业性执行必须紧密结合。製剂和给药方式的创新解决了长期存在的依从性和耐受性挑战，而数位健康和​​真实世界证据计划则重新定义了价值的体现方式。同时，贸易政策的发展和日益复杂的供应链迫使製造商重新思考筹资策略，并增强其营运的韧性。

相关人员若能将产品开发、证据产生和上市工作协调一致，则最有可能获得长期价值。这需要持续关注患者和付款人关注的成果，制定灵活的商业计划以应对区域动态，并投资于将临床差异化转化为可衡量的医疗效益的能力。透过全面考虑临床、监管和物流，组织可以从被动规划转向主动策略执行，从而支持患者照护和商业性永续性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 基于感测器技术的真实世界证据支持新型非典型抗精神病药物的长期安全性
  • 思觉失调症
  • 受体偏向促效剂的出现，可最大限度地减少下一代抗精神病药物的代谢副作用
  • 透过抗精神病治疗中的药物基因组学测试扩​​展个人化医疗
  • 开发长效注射剂以提高早期精神病患者的治疗连续性

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 抗精神病药物市场（依药物类别）

  • 第一代抗精神病药物
    • 氯丙嗪
    • 氟奋乃静
    • Haloperidol
    • 奋乃静
    • 硫利达嗪
  • 第二代抗精神病药物
    • Aripiprazole
    • 氯氮平
    • Olanzapine
    • Quetiapine
    • Risperidone

9. 抗精神病药物市场（依给药途径）

  • 注射
    • 肌肉注射
    • 长效注射剂
  • 口服

第 10 章抗精神病药物市场（按分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 11 章：抗精神病药物市场（按处方）

  • 口溶锭
  • 解决方案
  • 药片

第 12 章：抗精神病药物市场（按适应症）

  • 躁郁症
  • 思觉失调症

第 13 章：抗精神病药物市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 14 章。抗精神病药物市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。各国抗精神病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Otsuka Holdings Co., Ltd.
    • Johnson & Johnson
    • AstraZeneca plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Novartis AG
    • H. Lundbeck A/S
    • Teva Pharmaceutical Industries Ltd.
    • Mylan NV
    • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-AD36CD897CDF

The Antipsychotic Drugs Market is projected to grow by USD 19.65 billion at a CAGR of 8.25% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.42 billion
Estimated Year [2025] USD 11.28 billion
Forecast Year [2032] USD 19.65 billion
CAGR (%) 8.25%

A comprehensive contextual introduction that frames clinical imperatives, delivery models, and stakeholder priorities transforming antipsychotic therapy pathways

The therapeutic landscape for antipsychotic drugs sits at the intersection of clinical necessity, policy pressures, and commercial transformation. Over recent years, advances in molecular pharmacology, refinements in formulation technology, and shifts in care delivery models have together reshaped how clinicians and health systems approach treatment for schizophrenia and bipolar disorder. Patients increasingly demand tolerability alongside efficacy, payers insist on demonstrable value, and manufacturers must balance lifecycle management with novel product development.

Given this context, strategic stakeholders require a concise orientation that highlights the drivers influencing prescribing behavior, formulary placement, and patient adherence. To that end, it is critical to consider both the legacy role of first generation antipsychotics and the expanding therapeutic footprint of second generation agents, while also recognizing how routes of administration and evolving distribution channels influence real-world access. This introduction frames those dynamics and sets expectations for the deep-dive analyses that follow, emphasizing clinical outcomes, supply chain continuity, and payer engagement as core themes.

An analysis of converging clinical, technological, and evidence-generation forces that are redefining antipsychotic treatment paradigms and stakeholder expectations

The antipsychotic landscape is undergoing transformative shifts driven by patient-centric care models, pharmacological innovation, and broader health system modernization. Precision in agent selection has moved beyond symptomatic control to encompass metabolic risk mitigation, cognitive outcomes, and long-term functional recovery. Concurrently, formulation science has enabled new delivery options that improve adherence and reduce relapse risk, which in turn alters the calculus for hospital and outpatient care planning.

At the same time, digital health tools and telepsychiatry are expanding diagnostic reach and enabling closer monitoring of treatment response and adverse effects. These technologies are fostering shared decision-making between clinicians and patients and are beginning to influence prescribing patterns by making ongoing assessment more practical. Moreover, an emphasis on real-world evidence is changing the evidentiary bar for payer coverage decisions, with health systems increasingly focused on longitudinal outcomes and healthcare utilization metrics rather than isolated trial endpoints. These combined shifts are prompting manufacturers to align clinical development, commercial strategy, and post-market evidence generation more tightly than ever before.

A focused evaluation of how recent United States tariff changes are reshaping supply chain strategies, sourcing choices, and competitive positioning in antipsychotic drug commercialization

Policy instruments such as tariffs can have material downstream effects across the pharmaceutical value chain, particularly when applied to active pharmaceutical ingredients, specialized excipients, and finished dosage imports. In 2025, trade policy adjustments have introduced a period of elevated uncertainty for manufacturers and distributors that rely on cross-border sourcing of APIs and finished products. As a result, procurement strategies are shifting to emphasize supplier diversification and inventory resilience, while commercial teams reassess cost-to-serve assumptions across distribution channels.

These trade-related dynamics also influence the competitive environment. Where tariff pressures increase the landed cost of imported products, manufacturers with domestic or near-shore production capacity can gain relative commercial flexibility. Conversely, companies dependent on complex international supply chains may prioritize contractual hedging, renegotiation with suppliers, and operational investments to mitigate exposure. Trade policy uncertainty can therefore accelerate strategic moves such as localized manufacturing, increased vertical integration of API supply, and closer collaboration with contract manufacturing organizations that have regional footprints. Importantly, clinical programs and regulatory filings remain governed by existing safety and efficacy standards, but timelines for product launches and lifecycle initiatives may be affected by logistical constraints and cost management decisions.

Actionable segmentation insights that align drug class, administration route, distribution channel, formulation, and indication to optimize clinical adoption and commercial focus

Robust segmentation clarifies where clinical need, adoption patterns, and commercial opportunity intersect. By drug class, the market differentiates between first generation antipsychotics and second generation antipsychotics, with first generation agents including Chlorpromazine, Fluphenazine, Haloperidol, Perphenazine, and Thioridazine, while second generation agents include Aripiprazole, Clozapine, Olanzapine, Quetiapine, and Risperidone. Each class presents distinct therapeutic profiles, tolerability considerations, and prescriber preferences that affect positioning strategies.

By route of administration, products are categorized as Injectable and Oral, with Injectable formulations further distinguished by intramuscular and long-acting injectable options; the choice of route directly affects adherence, relapse prevention, and the operational requirements of care settings. Distribution channels encompass Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy, which shape patient access models, dispensing practices, and payer interactions. Formulation distinctions such as Orally Disintegrating Tablets, Solution, and Tablets influence patient acceptability and site-of-care decisions. Finally, indication segmentation across Bipolar Disorder and Schizophrenia underscores differences in clinical pathways, treatment duration expectations, and outcomes metrics. Together, these segmentation lenses enable targeted go-to-market approaches, evidence-generation plans, and portfolio prioritization that respond to both clinical and commercial realities.

Regional strategic intelligence examining how distinct healthcare systems, reimbursement frameworks, and access dynamics influence antipsychotic adoption across global markets

Regional dynamics continue to shape clinical practice, regulatory interpretation, and distribution logistics in distinct ways. In the Americas, healthcare delivery trends emphasize integrated behavioral health services, expanding community-based care, and payer-driven value assessments that prioritize outcomes and cost-effectiveness. These factors influence formulary placement decisions and encourage investment in long-acting injectables where adherence challenges drive avoidable utilization.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with localized reimbursement approaches; this region shows varied adoption speeds for newer agents and formulations based on national health technology assessment processes and funding priorities. Manufacturers must tailor evidence packages and pricing strategies to meet diverse national requirements. In Asia-Pacific, rapid urbanization, evolving insurance coverage, and expanding mental health awareness are creating increased demand for broad access options, including oral therapies and digital adherence tools. Across all regions, supply chain resilience, regulatory compliance, and culturally appropriate patient engagement are critical for successful product launches and sustained uptake. Moreover, geopolitical and policy shifts can introduce regional variability in procurement and distribution that commercial strategies must accommodate.

Insightful company-level analysis revealing how portfolio depth, formulation innovation, and strategic partnerships drive competitive advantage in antipsychotic therapeutics

Competitive positioning in antipsychotic therapeutics reflects a blend of legacy portfolios, novel formulations, and differentiated clinical evidence. Established companies maintain significant presence through foundational agents and broad distribution networks, while specialist innovators focus on improving tolerability, adherence, and long-term functional outcomes. Partnerships between originators and contract manufacturers remain common for scaling production, and alliances with technology providers are increasingly relevant for adherence and monitoring solutions.

R&D pipelines emphasize both incremental innovations-such as improved delivery systems and reformulations-and novel mechanisms targeting symptom domains with better metabolic profiles. Commercial teams that succeed are those which align lifecycle management with real-world evidence accumulation, prioritize payer engagement early, and maintain adaptive supply strategies to mitigate trade and sourcing volatility. Additionally, talent investment in regulatory affairs and health economics expertise is becoming a core competency, enabling firms to navigate complex reimbursement environments and demonstrate comparative value.

Actionable strategic recommendations for manufacturers and stakeholders to strengthen resilience, evidence generation, and payer-aligned commercialization in antipsychotic care

Industry leaders should pursue a coordinated strategy that balances near-term operational resilience with longer-term clinical differentiation. First, fortify supply chains by diversifying API and excipient sourcing, expanding near-shore manufacturing where feasible, and establishing transparent inventory and contingency planning. This will reduce exposure to trade-related disruptions and support predictable product availability across channels.

Second, invest in formulation and delivery innovations that directly address adherence and tolerability challenges, such as long-acting injectables and orally disintegrating tablets, while pairing these products with digital adherence and monitoring solutions to generate compelling real-world evidence. Third, engage payers proactively by developing outcomes-based evidence packages that reflect longitudinal benefits and reduced healthcare utilization. Fourth, adopt flexible commercial models that tailor distribution strategies to local channel dynamics-whether hospital pharmacy, online pharmacy, or retail pharmacy-and prioritize patient support programs that enhance initiation and persistence. Finally, cultivate cross-functional capabilities in health economics, regulatory strategy, and data analytics to ensure that clinical value propositions translate into reimbursement and sustainable uptake.

A transparent research methodology combining clinical literature synthesis, expert interviews, and supply chain analysis to support defensible strategic conclusions

This research synthesis integrates multi-source evidence to provide a transparent and reproducible foundation for strategic decisions. The methodology combines systematic literature review of peer-reviewed clinical studies, analysis of regulatory guidance and labeling changes, and structured interviews with clinical experts, payers, and commercial leaders to capture real-world perspectives. Additionally, supply chain assessments draw on logistics and procurement data to evaluate sourcing dependencies and regional manufacturing footprints.

Qualitative inputs were triangulated with secondary data on prescribing patterns and care-delivery trends to construct robust thematic conclusions. Wherever possible, findings were validated through expert advisory panels to ensure practical relevance and to surface anticipatory risks. The approach emphasizes traceability in data sourcing and clarity in analytical assumptions, enabling stakeholders to interpret conclusions within the appropriate clinical and commercial context. Limitations include the dynamic nature of policy and tariff environments, which necessitates periodic reassessment as trade and regulatory conditions evolve.

A decisive concluding synthesis emphasizing alignment of clinical differentiation, evidence generation, and resilient commercialization strategies for long-term impact

In conclusion, the antipsychotic therapeutics arena is at an inflection point where clinical expectations, payer scrutiny, and commercial execution must be tightly integrated. Innovations in formulation and delivery are addressing longstanding adherence and tolerability challenges, while digital health and real-world evidence initiatives are redefining how value is demonstrated. Concurrently, trade policy developments and supply chain complexities are encouraging manufacturers to reconsider sourcing strategies and to strengthen operational resilience.

Stakeholders who align product development, evidence generation, and market access efforts will be best positioned to capture long-term value. This requires a sustained focus on outcomes that matter to patients and payers, agile commercial planning responsive to regional dynamics, and investment in capabilities that translate clinical differentiation into measurable healthcare benefits. By synthesizing clinical, regulatory, and logistical considerations, organizations can move from reactive planning to proactive strategic execution that supports both patient care and commercial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Real world evidence supporting long term safety profiles of novel atypical antipsychotics based on sensor technology
  • 5.2. Integration of digital therapeutics and mobile monitoring to enhance adherence in schizophrenia patients
  • 5.3. Emergence of receptor biased agonists minimizing metabolic side effects in next generation antipsychotics
  • 5.4. Expansion of personalized medicine through pharmacogenomic testing in antipsychotic therapy
  • 5.5. Development of long acting injectable formulations improving treatment continuity in early psychosis patients

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antipsychotic Drugs Market, by Drug Class

  • 8.1. First Generation Antipsychotics
    • 8.1.1. Chlorpromazine
    • 8.1.2. Fluphenazine
    • 8.1.3. Haloperidol
    • 8.1.4. Perphenazine
    • 8.1.5. Thioridazine
  • 8.2. Second Generation Antipsychotics
    • 8.2.1. Aripiprazole
    • 8.2.2. Clozapine
    • 8.2.3. Olanzapine
    • 8.2.4. Quetiapine
    • 8.2.5. Risperidone

9. Antipsychotic Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intramuscular
    • 9.1.2. Long Acting Injectable
  • 9.2. Oral

10. Antipsychotic Drugs Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Antipsychotic Drugs Market, by Formulation

  • 11.1. Orally Disintegrating Tablets
  • 11.2. Solution
  • 11.3. Tablets

12. Antipsychotic Drugs Market, by Indication

  • 12.1. Bipolar Disorder
  • 12.2. Schizophrenia

13. Antipsychotic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antipsychotic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antipsychotic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Otsuka Holdings Co., Ltd.
    • 16.3.2. Johnson & Johnson
    • 16.3.3. AstraZeneca plc
    • 16.3.4. Eli Lilly and Company
    • 16.3.5. Pfizer Inc.
    • 16.3.6. Novartis AG
    • 16.3.7. H. Lundbeck A/S
    • 16.3.8. Teva Pharmaceutical Industries Ltd.
    • 16.3.9. Mylan N.V.
    • 16.3.10. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIPSYCHOTIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIPSYCHOTIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CHLORPROMAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FLUPHENAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HALOPERIDOL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY PERPHENAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY THIORIDAZINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ARIPIPRAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY CLOZAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY OLANZAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY QUETIAPINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RISPERIDONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY LONG ACTING INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ORALLY DISINTEGRATING TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY BIPOLAR DISORDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 264. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 268. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 281. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 286. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 301. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 302. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 303. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 304. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 312. GLOBAL ANTIPSYCHOTIC DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY FIRST GENERATION ANTIPSYCHOTICS, 2025-2032 (USD MILLION)
  • TABLE 319. ASEAN ANTIPSYCHOTIC DRUGS MARKET SIZE, BY SECOND GENERATION